MSD Signs Agreement For New Laboratory Space at The Francis Crick Institute
March 9, 2023 9:00 am +00:00
New, 1098m2 laboratory to provide interim space for company’s expanding interdisciplinary team of London-based discovery scientists
LONDON, March 9, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK)) announced today an expansion of its scientific footprint in London, having signed a 3-year agreement to occupy new laboratory space to be built on the roof of The Francis Crick Institute. Construction of the new “Skylab” is due to be completed in 2024.
MSD has a rapidly growing interdisciplinary team of discovery scientists in London with expertise spanning biology, chemistry and pharmacology. The new laboratory space allows for further expansion of the MSD discovery team, with capacity for an additional 50 personnel. This is the latest phase of preparation for the opening of MSD’s new UK Discovery Centre and Headquarters to be strategically located in the Kings Cross area, at the heart of London’s Knowledge quarter. The new facility is due to be completed in 2027.
During a recent visit to The Crick, Dr, Dean Y. Li, President of MSD Research Labs, commented:
“Our talented team of London based scientists is an important and growing part of our discovery network. We are pleased to collaborate with the Francis Crick Institute which provides an active and vibrant setting for life science research.”
The MSD London discovery teams, currently located at The Francis Crick Institute and The London BioScience Innovation Centre (LBIC), have ongoing collaborations with several leading UK institutions, including a Framework Collaboration, jointly funded with the Crick. In addition to many other bespoke academic collaborations within the U.K. and Europe, MSD is a member of several major human health and disease-specific consortia in human health and disease.
Sir Paul Nurse, Director of The Francis Crick Institute, commented:
“We’re delighted to welcome an expanded team of scientists from MSD to work in the Skylab here at the Crick. It is vital that we harness our discoveries in fundamental biology for the benefit of society. Our partnership with MSD helps this to be done and this development signals the Crick’s commitment to working as partners in London in the longer term.”
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd-uk.com.
GB-NON-07161 | Date of Preparation: March 2023